Hutchmed (HCM) announces that the new drug application for the combination of Orpathys and Tagrisso for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration. The acceptance also triggers a milestone payment from AstraZeneca (AZN), the company said in a statement.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCM:
- Hutchmed divests 45% interest in Shanghai Hutchison for $608M
- Hutchmed to receive milestone payment from Takeda
- Hutchmed announces BTD in China for Orpathys, Tagrisso combination
- Hutchmed announces Elunate, Tyvyt NDA granted approval in China
- Hutchmed to receive milestone payment following Takeda launch of Fruzaqla